The Leucine Rich Repeat Kinase pipeline drugs market research report outlays comprehensive information on the Leucine Rich Repeat Kinase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Leucine Rich Repeat Kinase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Oncology, Immunology, and Ophthalmology which include the indications Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Pancreatic Cancer, Glioblastoma Multiforme (GBM), Immunology, Ocular Hypertension, and Open-Angle Glaucoma. It also reviews key players involved in Leucine Rich Repeat Kinase targeted therapeutics development with respective active and dormant or discontinued products.
The Leucine Rich Repeat Kinase pipeline targets constitutes close to 30 molecules. Out of which, approximately 29 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical, and Discovery stages are 3, 6, 13, and 7 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Leucine Rich Repeat Kinase overview
Leucine-rich repeat kinase 2 (LRRK2) is a serine/threonine-protein kinase that phosphorylates a broad range of proteins involved in multiple processes such as neuronal plasticity, innate immunity, autophagy, and vesicle trafficking. Is a key regulator of RAB GTPases by regulating the GTP/GDP exchange and interaction partners of RABs through phosphorylation.
For a complete picture of Leucine Rich Repeat Kinase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
